论文部分内容阅读
TORCH临床研究关于总生存期的结果终于发表了,结果似乎没有悬念。厄洛替尼可以延长非选择的不适合继续化疗的晚期非小细胞肺癌患者的生存。有二项Ⅱ期临床研究建议厄洛替尼可替代一线化疗。TORCH为Ⅲ期临床研究,旨在验证晚期非小细胞肺癌患者一线厄洛替尼二线顺铂-吉西他滨是否非劣于一线顺铂-吉西他滨二线厄洛替尼。选择人群为ⅢB期(胸腔积液或者锁骨上淋巴结转移)～Ⅳ期患
TORCH clinical study on the results of the total survival was finally published, the result seems to be no suspense. Erlotinib can prolong the survival of non-selected advanced non-small cell lung cancer patients who are not eligible for further chemotherapy. There are two phase II clinical studies suggest that erlotinib can replace first-line chemotherapy. TORCH is a Phase III clinical trial designed to validate whether first-line erlotinib second-line cisplatin-gemcitabine is superior to first-line cisplatin-gemcitabine second-line erlotinib in patients with advanced non-small cell lung cancer. Select the crowd for stage Ⅲ B (pleural effusion or supraclavicular lymph node metastasis) ~ Ⅳ disease